BMO Capital on Novo Nordisk (NVO): 'FDA Approval Brings Much-Needed Cheer'
Tweet Send to a Friend
BMO Capital analyst Evan Seigerman reiterated a Market Perform rating and $46.00 price target on Novo Nordisk (NYSE: NVO).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
